Retatrutide
Triple-receptor research compound. GLP-1 / GIP / glucagon pathway investigation.
RESTRICTED ACCESS
All products on this site are research chemicals sold strictly for laboratory and analytical purposes. Not for human or animal consumption. Confirm the following to enter.
I do not agree, exitMETABOLIC & GLP-1
High-dose triple-agonist research peptide. GLP-1, GIP, and glucagon receptor engagement.
ABOUT THIS COMPOUND
The 30 mg presentation of Retatrutide is intended for higher-volume research protocols where multiple study arms or extended-duration investigations are required. Same molecule, same synthesis chain, additional capacity per vial.
Retatrutide is investigated for its triple-pathway pharmacology across the GLP-1, GIP, and glucagon receptors. Each lot is solid-phase synthesized in our U.S. facility, HPLC-verified above 99% purity, lyophilized under inert atmosphere.
SPECIFICATIONS
RESEARCH APPLICATIONS
All applications are investigative. This compound is sold for research-use only and is not for human or animal consumption.
QUALITY ASSURANCE
A current-lot Certificate of Analysis is available for every compound. Email us with the product and lot number; we'll send the documentation. Read about our lab testing →
YOU MAY ALSO RESEARCH
QUESTIONS?
Lot questions, COA requests, institutional accounts, reach the team directly.
CONTACT US